- Home
- DGX
as 11-15-2024 4:00pm EST
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | SECAUCUS |
| Market Cap: | 17.5B | IPO Year: | 1996 |
| Target Price: | $163.38 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.44 | EPS Growth: | 11.56 |
| 52 Week Low/High: | $123.04 - $162.59 | Next Earning Date: | 10-22-2024 |
| Revenue: | $9,539,000,000 | Revenue Growth: | 2.60% |
| Revenue Growth (this year): | 7.33% | Revenue Growth (next year): | 8.69% |
Stock Insider Trading Activity of Quest Diagnostics Incorporated (DGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KUPPUSAMY KARTHIK | DGX | SVP, Clinical Solutions | Oct 28 '24 | Sell | $156.92 | 1,775 | $278,525.19 | 9,734 | |
| PREVOZNIK MICHAEL E | DGX | SVP & General Counsel | Aug 29 '24 | Sell | $154.97 | 32,551 | $5,044,516.36 | 38,478 | |
| KUPPUSAMY KARTHIK | DGX | SVP, Clinical Solutions | Aug 28 '24 | Sell | $153.26 | 1,990 | $304,989.79 | 9,734 |
Latest Quest Diagnostics Incorporated News
DGX Breaking Stock News: Dive into DGX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
SYK Stock Rises Following the Launch of Next Generation SurgiCount+
Simply Wall St.
2 days ago
Quest Diagnostics Incorporated's (NYSE:DGX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Zacks
3 days ago
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System
Zacks
4 days ago
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy
Zacks
4 days ago
Cardinal Health Stock Gains Following Two Strategic Acquisitions
Zacks
4 days ago
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
Zacks
4 days ago
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
PR Newswire
5 days ago
Quest Diagnostics Declares Quarterly Cash Dividend
Compare DGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DGX Quest Diagnostics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.